Last reviewed · How we verify

Tonic-Clonic Epilepsy Treatment Adjunct — Treatment Landscape & Competitive Intelligence

Tonic-Clonic Epilepsy Treatment Adjunct (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Tonic-Clonic Epilepsy Treatment Adjunct, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Keppra levetiracetam Generic (originally UCB Pharma) Antiepileptic agent Synaptic vesicle protein SV2A 1999-11-30
Keppra Keppra Masonic Cancer Center, University of Minnesota Carbonic anhydrase 1, Sodium channel protein type 1 subunit alpha, Synaptic vesicle glycoprotein 2A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Generic (originally UCB Pharma) · 1 drug in Tonic-Clonic Epilepsy Treatment Adjunct
  2. Masonic Cancer Center, University of Minnesota · 1 drug in Tonic-Clonic Epilepsy Treatment Adjunct

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Tonic-Clonic Epilepsy Treatment Adjunct:

Cite this brief

Drug Landscape (2026). Tonic-Clonic Epilepsy Treatment Adjunct — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/tonic-clonic-epilepsy-treatment-adjunct. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing